loader
Please Wait
Applying Filters...

Seqens Seqens

X

Technical details about Sodium 4-Phenylbutyrate, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
Also known as: Sodium 4-phenylbutyrate, 1716-12-7, Sodium 4-phenylbutanoate, Buphenyl, Tributyrate, Ammonaps
Molecular Formula
C10H11NaO2
Molecular Weight
186.18  g/mol
InChI Key
VPZRWNZGLKXFOE-UHFFFAOYSA-M
FDA UNII
NT6K61736T

1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
sodium;4-phenylbutanoate
2.1.2 InChI
InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
2.1.3 InChI Key
VPZRWNZGLKXFOE-UHFFFAOYSA-M
2.1.4 Canonical SMILES
C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
2.2 Other Identifiers
2.2.1 UNII
NT6K61736T
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-phenylbutyrate

2. 4-phenylbutyric Acid

3. 4-phenylbutyric Acid, Calcium Salt

4. 4-phenylbutyric Acid, Sodium Salt

5. Ammonaps

6. Buphenyl

7. Sodium 4-phenylbutanoate

8. Sodium 4-phenylbutyrate

2.3.2 Depositor-Supplied Synonyms

1. Sodium 4-phenylbutyrate

2. 1716-12-7

3. Sodium 4-phenylbutanoate

4. Buphenyl

5. Tributyrate

6. Ammonaps

7. Benzenebutanoic Acid, Sodium Salt

8. 4-phenylbutyric Acid Sodium Salt

9. Sodium;4-phenylbutanoate

10. 4-phenylbutyric Acid Sodium

11. 4-phenylbutyric Acid, Sodium Salt

12. Acer-001

13. Chebi:75316

14. Nt6k61736t

15. Mfcd00800247

16. Nsc-657802

17. Amx0035 Component Sodium Phenylbutyrate

18. Dsstox_cid_20948

19. Dsstox_rid_79606

20. Dsstox_gsid_40948

21. Pheburane

22. 4pba

23. Sodium Phenylbutyrate [usan]

24. Cas-1716-12-7

25. Ncgc00018113-03

26. Nsc 657802

27. Ammonapse

28. Lunaphen

29. Unii-nt6k61736t

30. Napb

31. Phenylbutyrate Na

32. Sodium Phenylbutyrate [usan:ban]

33. Buphenyl (tn)

34. El-532

35. Vp-101

36. 4-phenylbutyric Acid Sodium 100 Microg/ml In Acetonitrile:water

37. Sodium-4-phenylbutyrate

38. Chembl1746

39. Sodium 4-phenylbutyrate-d11

40. Phenylbutyric Acid Sodium Salt

41. Schembl125792

42. 4-pb

43. Sodium 4-phenylbutyrate, 95%

44. Dtxsid7040948

45. Cmk-304

46. Sodium Phenylbutyrate (jan/usp)

47. Hms2089b22

48. Hms3269n07

49. Hms3413b10

50. Hms3652k18

51. Hms3677b10

52. Hms3885p05

53. Sodium Phenylbutyrate [mi]

54. Sodium Phenylbutyrate [jan]

55. Amy13389

56. Sodium 4-phenylbutyrate;tributyrate

57. Tox21_110826

58. Phenylbutyrate Sodium [vandf]

59. S4125

60. Sodium Phenylbutyrate [mart.]

61. Akos006344763

62. Akos015967141

63. Sodium Phenylbutyrate [usp-rs]

64. Sodium Phenylbutyrate [who-dd]

65. Tox21_110826_1

66. Ccg-213730

67. Ccg-265014

68. Cs-1397

69. Sodium Phenylbutyrate [ema Epar]

70. Sodium Phenylbutyrate, >=98% (hplc)

71. Ncgc00018113-07

72. Ncgc00167830-01

73. As-13914

74. Hy-15654

75. Sy067225

76. Sodium Phenylbutyrate [orange Book]

77. Sodium Phenylbutyrate [ep Monograph]

78. A4107

79. Ft-0619402

80. O0511

81. Sodium Phenylbutyrate [usp Monograph]

82. Sw219199-1

83. D05868

84. F14969

85. Amx-0035 Component Sodium Phenylbutyrate

86. A811337

87. J-010746

88. J-524277

89. Q7553358

90. Sodium Phenylbutyrate, European Pharmacopoeia (ep) Reference Standard

91. Sodium Phenylbutyrate, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 186.18 g/mol
Molecular Formula C10H11NaO2
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count2
Rotatable Bond Count4
Exact Mass186.06567387 g/mol
Monoisotopic Mass186.06567387 g/mol
Topological Polar Surface Area40.1 Ų
Heavy Atom Count13
Formal Charge0
Complexity142
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameBuphenyl
PubMed HealthSodium Phenylbutyrate (By mouth)
Drug ClassesHyperammonemia Agent, Nutritive Agent
Drug LabelBUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su...
Active IngredientSodium phenylbutyrate
Dosage FormTablet; Powder
RouteOral
Strength3gm/teaspoonful; 500mg
Market StatusPrescription
CompanyHyperion Theraps

2 of 4  
Drug NameSodium phenylbutyrate
PubMed HealthSodium Phenylbutyrate (By mouth)
Drug ClassesHyperammonemia Agent, Nutritive Agent
Drug LabelBUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su...
Active IngredientSodium phenylbutyrate
Dosage FormTablet; Powder
RouteOral
Strength500mg; 3gm/teaspoonful
Market StatusPrescription
CompanySigmapharm Labs; Ampolgen

3 of 4  
Drug NameBuphenyl
PubMed HealthSodium Phenylbutyrate (By mouth)
Drug ClassesHyperammonemia Agent, Nutritive Agent
Drug LabelBUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su...
Active IngredientSodium phenylbutyrate
Dosage FormTablet; Powder
RouteOral
Strength3gm/teaspoonful; 500mg
Market StatusPrescription
CompanyHyperion Theraps

4 of 4  
Drug NameSodium phenylbutyrate
PubMed HealthSodium Phenylbutyrate (By mouth)
Drug ClassesHyperammonemia Agent, Nutritive Agent
Drug LabelBUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su...
Active IngredientSodium phenylbutyrate
Dosage FormTablet; Powder
RouteOral
Strength500mg; 3gm/teaspoonful
Market StatusPrescription
CompanySigmapharm Labs; Ampolgen

4.2 Drug Indication

Treatment of chronic management of urea-cycle disorders.


Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or

argininosuccinate synthetase.

It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease

(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Nitrogen Binding Agent [EPC]; Ammonium Ion Binding Activity [MoA]
5.3 ATC Code

A16AX03


A16AX03


A - Alimentary tract and metabolism

A16 - Other alimentary tract and metabolism products

A16A - Other alimentary tract and metabolism products

A16AX - Various alimentary tract and metabolism products

A16AX03 - Sodium phenylbutyrate


Post Enquiry
POST ENQUIRY